GlassScriptPhysician profile
Peter J Garcia
NPI 1205832763
$5,219.70
in general payments reported to CMS, 2019-2025
29 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $485 · 2023: $1,579 · 2024: $1,383 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050 · Education: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.34 |
| Education | $565.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,179.45 | 2023-2025 | Gemtesa, Orgovyx |
| Antares Pharma, INC. | $637.45 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $631.37 | 2022-2025 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $339.47 | 2022-2025 | |
| Urovant Sciences INC | $329.37 | 2022 | |
| Teleflex LLC | $270.88 | 2024-2025 | Urolift |
| Accord Healthcare, INC. | $263.02 | 2023-2025 | |
| Abbvie INC. | $240.87 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $233.10 | 2021-2024 | Xiaflex, Aveed |
| Halozyme INC | $193.61 | 2023 | |
| Pfizer INC. | $157.28 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $90.61 | 2024-2025 | Tlando, Trelstar |
| Endo USA, INC. | $89.40 | 2024-2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $83.43 | 2023-2025 | Erleada |
| Sun Pharmaceutical Industries INC. | $65.62 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51.90 | 2022-2023 | Lynparza |
| Merck Sharp & Dohme LLC | $48.22 | 2023-2024 | Lynparza, Keytruda |
| Ultragenyx Pharmaceutical INC. | $38.44 | 2023-2024 | Crysvita |
| Boston Scientific Corporation | $35.77 | 2024 | Spaceoar Vue System - 10ml |
| C. R. Bard, INC. & Subsidiaries | $35.23 | 2023 | Bard Urinary Drainage Bag |
| Amgen INC. | $31.20 | 2021 | |
| Tempus Ai, INC | $29.88 | 2025 | Xt Cdx |
| Profound Medical Corp. | $27.05 | 2025 | Tulsa-Pro |
| Urogen Pharma, INC. | $26.90 | 2023 | Jelmyto |
| Ferring Pharmaceuticals INC. | $23.20 | 2025 | Adstiladrin |
| Myovant Sciences INC. | $18.83 | 2021 | |
| Immunitybio, INC. | $16.90 | 2024 | |
| Dendreon Pharmaceuticals LLC | $16.60 | 2025 | Provenge |
| Coloplast Corp | $14.65 | 2023 | Speedicath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.